BioOrchestra has succeeded in a technology export deal worth up to $861 million (approximately 1.121 trillion KRW).
On the 27th, BioOrchestra announced that it had signed an exclusive research and option agreement with a global pharmaceutical and biotech company for the development of nucleic acid therapeutics targeting various brain neurological disorders using BioOrchestra's drug delivery system (DDS), BDDS.
BioOrchestra was founded in 2016 by co-CEOs Jin-Hyup Ryu, Ph.D. in Pathology, Immunology, and Microbiology from the University of Tokyo School of Medicine, Japan, and Hyun-Jung Cho, professor in Clinical Pathology at Konyang University College of Medicine. Since 2019, the company has been operated under the sole leadership of CEO Ryu. BioOrchestra's BDDS is a DDS developed to efficiently enable gene therapy substances such as antisense oligonucleotides (ASO), messenger ribonucleic acid (mRNA), and short interfering RNA (siRNA) to cross the blood-brain barrier (BBB) and be stably delivered into the brain. In the development of brain disease therapeutics, if the therapeutic substances cannot cross the BBB, the drug's efficacy is difficult to achieve, making the development of effective BBB crossing methods a major challenge.
Regarding this contract, CEO Ryu said, "We are pleased to start this collaboration with our U.S. partner," adding, "We will accelerate the development program to provide innovative new drugs to patients together."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
